Literature DB >> 30679169

Increased Growth Differentiation Factor 15 Is Associated with Unfavorable Clinical Outcomes of Acute Ischemic Stroke.

Jieyun Yin1, Zhengbao Zhu1, Daoxia Guo1, Aili Wang1, Nimei Zeng1, Xiaowei Zheng1, Yanbo Peng2, Chongke Zhong1, Guangli Wang1, Yiting Zhou1, Chung-Shiuan Chen3, Jing Chen3,4, Yonghong Zhang5, Jiang He3,4.   

Abstract

BACKGROUND: Growth differentiation factor 15 (GDF-15), a stress-responsive biomarker, is known to be independently associated with mortality and cardiovascular events in different disease settings, but data on the prognostic value of GDF-15 after stroke are limited.
METHODS: Baseline serum GDF-15 was measured in 3066 acute ischemic stroke patients from the China Antihypertensive Trial in Acute Ischemic Stroke (CATIS). The primary outcome was a composite of death and major disability within 3 months. Secondary outcomes included death, major disability, vascular events, and stroke recurrence. The associations between GDF-15 and clinical outcomes after stroke were assessed by multivariate logistic regression or Cox proportional hazards models.
RESULTS: At 3 months' follow-up, 676 (22.05%), 86 (2.80%), 81 (2.64%), and 51 (1.66%) patients had experienced major disability, death, vascular events, or stroke recurrence, respectively. After adjusting for age, sex, current smoking, alcohol consumption, and baseline National Institutes of Health Stroke Scale score, the odds ratio/hazard ratio (95% CI) of 1 SD higher of base-10 log-transformed GDF-15 was 1.26 (1.15-1.39) for primary outcome, 1.13 (1.02-1.25) for major disability, 1.79 (1.48-2.16) for death, and 1.26 (1.00-1.58) for vascular events. The addition of GDF-15 to established risk factors improved risk prediction of the composite outcome of death and major disability (c-statistic, net reclassification index, and integrated discrimination improvement, all P < 0.05).
CONCLUSIONS: High GDF-15 concentrations are independently associated with adverse clinical outcomes of acute ischemic stroke, suggesting that baseline serum GDF-15 could provide additional information to identify ischemic stroke patients at high risk of poor prognosis.
© 2018 American Association for Clinical Chemistry.

Entities:  

Year:  2019        PMID: 30679169     DOI: 10.1373/clinchem.2018.297879

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

1.  Comprehensive Analysis of Blood-Based m6A Methylation in Human Ischemic Stroke.

Authors:  Lulu Zhu; Shengying Liu; Fangping Liao; Jialei Yang; Tian Liang; Yibing Yang; Xianli Huang; Lian Gu; Li Su
Journal:  Mol Neurobiol       Date:  2022-10-24       Impact factor: 5.682

2.  The Association Among Serum Growth Differentiation Factor 15 Level and Suicidal Ideation is Dependent on Testosterone Deficiency in Depressive Patients.

Authors:  Rui Peng; Di Li; Si-Qing Mei; Yan Li
Journal:  J Inflamm Res       Date:  2021-06-24

3.  Serum Growth Differentiation Factor 15 Levels Are Associated With Depression After Ischemic Stroke.

Authors:  Yuhan Zang; Zhengbao Zhu; Yi Xie; Zhen Liu; Jieyun Yin; Pinni Yang; Kaixin Zhang; Xiaoqing Bu; Aili Wang; Jing Chen; Yonghong Zhang; Jiang He
Journal:  J Am Heart Assoc       Date:  2021-12-31       Impact factor: 5.501

Review 4.  Growth differentiation factor 15 in adverse cardiac remodelling: from biomarker to causal player.

Authors:  Marian Wesseling; Julius H C de Poel; Saskia C A de Jager
Journal:  ESC Heart Fail       Date:  2020-05-18

5.  Growth Differentiation Factor 15: A Biomarker with High Clinical Potential in the Evaluation of Kidney Transplant Candidates.

Authors:  Marina de Cos Gomez; Adalberto Benito Hernandez; Maria Teresa Garcia Unzueta; Jaime Mazon Ruiz; Covadonga Lopez Del Moral Cuesta; Jose Luis Perez Canga; David San Segundo Arribas; Rosalia Valero San Cecilio; Juan Carlos Ruiz San Millan; Emilio Rodrigo Calabia
Journal:  J Clin Med       Date:  2020-12-20       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.